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Comparative effectiveness of immediate antiretroviral therapy 
versus CD4-based initiation in HIV-positive individuals in high-
income countries: observational cohort study
The HIV-CAUSAL Collaboration*
Summary
Background—Recommendations have differed nationally and internationally with respect to the 
best time to start antiretroviral therapy (cART). We compared effectiveness of three strategies for 
initiation of cART in high-income countries for HIV-positive individuals who do not have AIDS: 
immediate universal cART initiation, cART initiation at a CD4 cell count below 500, and cART 
initiation at a CD4 cell count below 350 cells/mm3.
Methods—We used data from the HIV-CAUSAL collaboration of cohorts in Europe and the 
United States. We included 55,826 individuals diagnosed with HIV between 2000-2013, ART 
naïve, AIDS-free, aged≥18 years and within 6 months of HIV diagnosis. We used the parametric 
g-formula to adjust for baseline and time-varying confounders to estimate the following quantities 
as would have been observed under each cART initiation strategy after 7 years of HIV diagnosis: 
relative risks of both death and of death or AIDS-defining illness, mean survival time, proportion 
in need of cART, and proportion with HIV RNA<50 copies/mL.
Findings—Median [interquantile range] CD4 at HIV diagnosis was 376 [222,551] cells/mm3. 
Compared with immediate initiation, the mortality risk ratio estimate (95% CI) was 1.02 
(1.01,1.02) under initiation at CD4<500 cells/mm3, and 1.06 (1.04,1.08) under initiation at 
CD4<350 cells/mm3. The corresponding estimates were 1.06 (1.06,1.07) and 1.20 (1.17,1.23) for 
the combined endpoint. Compared with immediate initiation, the mean survival time at 7 years 
under initiation at CD4<500 cells/mm3 and at CD4<350 cells/mm3 was 2 (1,2) and 5 (4,6) days 
shorter. Seven years after HIV diagnosis, 100%, 99%, and 93% of individuals would have been in 
need of cART, and 87%, 87% and 84% would have HIV-RNA<50 copies/mL, under immediate 
initiation, initiation at CD4<500 and <350 cells/mm3, respectively.
Interpretation—The benefits of immediate initiation of cART, such as prolonged survival and 
AIDS-free survival and increased virological suppression, were small in this high-income setting 
with relatively low CD4 count at HIV diagnosis. The estimated beneficial effect on AIDS is less 
than in recently reported randomised trials. Increasing rates of HIV testing might be as important 
as a policy of early initiation of cART.
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Panel: Research in context
Evidence before the study
Several observational studies and clinical trials have addressed the question of when to start combined antiretroviral therapy (cART). 
A summary of the evidence was presented in a systematic review and meta-analysis by WHO. Results of the TEMPRANO trial, and 
interim findings of the START trial, suggest that immediate initiation is the best cART initiation strategy. However, estimates from 
observational studies remain important to assess long-term outcomes of early cART initiation in populations representative of routine 
clinical practice.
Added value of this study
We have used data from a large collaboration of cohort studies in Europe and the USA to compare the effectiveness of three cART 
initiation strategies: immediate initiation; initiation at a CD4 count less than 500 cells/mm3 or a diagnosis of AIDS; and initiation at a 
CD4 count less than 350 cells/mm3 or a diagnosis of AIDS. The CD4 count at HIV diagnosis was low for many patients. In this 
population with a fairly low CD4 count at HIV diagnosis, immediate initiation increased survival and AIDS-free survival but, overall, 
the benefit was small. A strategy of immediate initiation of cART substantially increases the proportion of individuals with suppressed 
virological replication and the proportion of individuals in need of cART.
Implications of all the available evidence
Recent trials suggest that immediate initiation is the best ART initiation strategy. However, the benefi ts of a strategy of immediate 
initiation of cART, such as prolonged survival and AIDS-free survival and increased virological suppression, might be small in high-
income settings with relatively low CD4 count at HIV diagnosis. More widespread and frequent HIV testing is likely to be at least as 
important as a policy of early cART initiation.
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to start combined antiretroviral therapy (cART) in HIV-positive patients who do not have 
AIDS. In the most recent US guidelines,1,2 initiation of cART is recommended for all 
individuals who have been newly diagnosed with HIV infection, irrespective of their CD4 
count. By contrast with this guidance, WHO recommends initiation of cART when the 
patient’s CD4 count has fallen below 500 cells/mm3 Moreover, in Europe, treatment 
initiation is recommended for all patients with a CD4 count less than 350 cells/mm3 and 
should be considered for individuals with a CD4 count of 350–500 cells/mm3.
These discrepancies are attributable partly to different interpretations of available evidence. 
Over the past decade, findings of observational studies and clinical trials have shown that 
starting cART at CD4 counts of 350–500 cells/mm3 is associated with reduced mortality and 
AIDS morbidity5–12 and decreased transmission of HIV to other people.13 The benefits of 
such early initiation on survival and transmission might be off set by development of 
toxicity and drug resistance.14 Moreover, because treatment must be used for the rest of a 
patient’s life without interruption,15 immediate initiation would increase substantially the 
proportion of individuals in need of cART and the burden on available resources.
The results from the Temprano trial suggest that immediate universal initiation is the best 
cART initiation strategy in low-income countries with high risk of opportunistic 
infections12. Preliminary results from the Strategic Timing of Anti-Retroviral Treatment 
(START) trial also support the benefit of early initiation (http://www.ctu.mrc.ac.uk/news/
2015/start_results_28052015). However, there are no estimates of the relative effectiveness 
of immediate universal initiation versus initiation according to CD4 thresholds on the 
mortality and morbidity of populations representative of the clinical HIV practice in high-
income countries. These estimates are important not only to patients and clinicians but also, 
to service providers and policy makers who require estimates of the proportions of 
individuals in need of treatment and with suppressed viral load to estimate the cost-
effectiveness of current or future guidelines on cART initiation and to allocate resources 
between HIV treatment and other health priorities.
Here, we aimed to compare immediate initiation of cART with strategies for starting 
treatment based on CD4 thresholds of 350 cells/mm3 and 500 cells/mm3 in cohorts of HIV-
positive individuals from Europe and the USA. We aimed to compare clinical outcomes and 
the proportions of patients in need of treatment and with suppressed virological replication 
under each initiation strategy up to 7 years after HIV diagnosis.
Methods
Study population
The HIV-CAUSAL collaboration is a consortium of prospective cohort studies from 6 
European countries and the United States. All cohorts record routinely collected data in 
clinical practice within healthcare systems with universal access to care. Data collected 
include that related to patient characteristics (age, sex, geographical origin, and transmission 
category), use of cART (type of regimes and dates of start and discontinuation), CD4 cell 
counts, and plasma HIV-RNA, AIDS-defining illnesses, and deaths. Each cohort submits 
data in a standardized format (http://www.hicdep.org/) to the coordinating center. The 
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analyses presented here are based on data pooled in September 2013. Ethics approval was 
granted by the ethic committees of each of the participating cohorts according to country-
specific regulations.
Selection of patients
Analyses were restricted to individuals who met the following inclusion criteria: age ≥18 
years; HIV diagnosis on or after January 1, 2000; AIDS-free; antiretroviral therapy naïve; 
CD4 cell count and HIV-RNA measurements within 3 months of each other and within 6 
months of the date of HIV diagnosis. Follow-up started at baseline, defined as the date when 
all criteria were met, and ended at death (or AIDS when considering AIDS-free survival), 12 
months after the most recent laboratory measurement, or cohort-specific administrative 
censoring (ranging from 2011 to 2013), whichever occurred first. Individuals with no CD4 
cell count and HIV-RNA measurements after baseline were excluded. Since the relative 
effectiveness of initiation strategies will depend on CD4 count at HIV diagnosis, we also 
conducted two sensitivity analyses restricted to individuals with CD4>350 cells/mm3 and 
CD4>500 cells/mm3 at HIV diagnosis.
cART initiation strategies
cART was defined as a combination of antiretroviral drugs including at least two nucleoside 
reverse transcriptase inhibitors plus either one or more protease inhibitors, one 
nonnucleoside reverse transcriptase inhibitor, one entry/fusion inhibitor, or one integrase 
inhibitor.
We compared the following three cART initiation strategies: i) immediate universal 
treatment, defined as initiation within 6 months of HIV diagnosis regardless of the CD4 
count, ii) initiation within 6 months of a CD4 count <500 cells/mm3 or an AIDS diagnosis, 
and iii) initiation within 6 months of a CD4 cell count <350 cells/mm3 or an AIDS 
diagnosis.
Outcomes
We considered the following clinical outcomes: all-cause mortality and a combined endpoint 
of AIDS-defining illness16 or death. For each cART initiation strategy and outcome, we 
estimated the 7-year risk and the average restricted survival time17. In sensitivity analyses, 
we also considered a combined endpoint of death or severe or moderate AIDS-defining 
illness18 (non-Hodgkin's lymphoma, progressive multifocal leukoencephalopathy, 
cryptococcosis, cerebral toxoplasmosis, AIDS dementia complex and disseminated 
Mycobacterium avium complex), and the outcome tuberculosis as later treatment initiation 
has been associated with increased risk of tuberculosis10,13.
We also estimated the proportion of individuals considered in need of treatment and with 
suppressed virological replication, defined as HIV-RNA<50 copies/mL, up to 7 years after 
baseline, assuming that cART is continued once it is started.
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Our estimates need to be adjusted for the time-dependent confounders CD4 cell count, 
HIVRNA level and AIDS, as well as for confounders measured at baseline. Because 
standard statistical methods cannot appropriately adjust for time-dependent confounders 
affected by prior treatment 19,20, we applied the parametric g-formula to obtain adjusted 
estimates for each treatment strategy under the assumptions of no residual confounding, no 
measurement error, and no model misspecification21.
The parametric g-formula is a generalization of standardization for time-varying treatments 
and confounders5,20,21. The estimation procedure for the HIV-CAUSAL Collaboration has 
been described elsewhere 5. Briefly, the procedure has two steps. First, parametric 
regression models are used to estimate the probability density functions of the time-varying 
variables conditional on previous treatment and covariate history. Second, a Monte Carlo 
simulation using the above estimates is run to simulate the distribution of the post-baseline 
outcomes and time-varying covariates separately under each cART initiation strategy.
For the first step, we fit separate logistic regression models for time-varying indicators of 
death, AIDS-defining illness, cART initiation, measurement of CD4 cell count, 
measurement of HIV RNA, and linear regression models for CD4 cell count and HIV-RNA 
on the natural logarithm scale. All regression models included as covariates the two most 
recent values of these time-varying variables, time since last CD4 count and HIV-RNA 
measurements, and the following baseline variables: CD4 cell count 
(<50,50-99,100-199,200-349,350-499, ≥500 cells/mm3), HIV-RNA level (<4,4-5, >5 log10 
copies/mL), sex, transmission group (heterosexual, homo/bisexual, injecting drug users, or 
other/unknown), calendar year (2000-2004, 2005-2010, 2011-2013), age (<35,35-50, >50 
years), geographical origin (Western countries, sub-Saharan Africa, other, unknown), and 
cohort. Models for CD4 cell count and HIV-RNA also included an interaction term for 
number of months since cART initiation. Like all regression-based methods, the parametric 
g-formula relies on correct model specification. To explore the validity of our parametric 
assumptions, we compared the observed means of the outcome and time-varying covariates 
with those predicted by our models (Appendix Figure 1).
We used a nonparametric bootstrap procedure based on 200 samples to obtain percentile-
based 95% confidence intervals (CIs). All analyses were conducted with the publicly 
available SAS macro GFORMULA (http://www.hsph.harvard.edu/causal/software/).
Sensitivity analyses
We conducted several sensitivity analyses in which we (i) adjusted for a time-fixed indicator 
of hepatitis C co-infection, (ii) included individuals with no CD4 cell count and HIV-RNA 
measurements after baseline, (iii) excluded the cohorts of HIV seroconverters (GEMES, 
PRIMO, SEROCO, UK Register of Seroconverters) who might have been treated with 
short-course antiretroviral treatment during primary HIV infection (shown to be have 
immunological and virological benefits after treatment is stopped22-24), and (iv) computed 
the proportion of individuals with suppressed virological replication defined as HIV-
RNA<400 copies/mL rather than <50 copies/mL.
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Role of funding source
The funder had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full access to all data in the study and 
had final responsibility for the decision to submit for publication.
Results
The HIV-CAUSAL collaboration included 70,488 HIV positive individuals with known date 
of HIV diagnosis between 2000-2013. We excluded 5,027 who had no CD4 count or HIV-
RNA after baseline and 9,635 whose baseline date was >6 months after HIV diagnosis.
Table 1 shows the baseline characteristics of the 55,826 individuals eligible for our analyses: 
77% were men, 73% started follow-up after 2004; their median [IQR] CD4 cell count, HIV-
RNA and age at baseline were 376 [222,551] cells/mm3, 4.6 [4.0,5.1] log10 copies/mL and 
36 [30,44] years, respectively. During the follow-up 71% initiated cART. The median [IQR] 
CD4 cell count and HIV-RNA at cART initiation were 259 [161,355] cells/mm3 and 4.8 
[4.2,5.3] log10 copies/mL, respectively. The median [IQR] time between HIV diagnosis and 
cART initiation was 2 [1,14] months, and the proportion of initiators with CD4 cell count 
>500 cells/mm3 was 9%. Compared with individuals who initiated cART with CD4 cell 
count ≤500 cells/mm3, those who initiated cART with CD4 count>500 cells/mm3 were less 
likely to be immigrants and more likely to be in the homosexual/bisexual transmission group 
(Appendix Table 1).
During 215,521 person-years of follow-up 1,737 individuals died and 3,472 developed an 
AIDS-defining illness or died. The estimated 7-year risk (95% CI) of death was 4.0% (3.8, 
4.2) for immediate cART initiation, 4.0% (3.8, 4.3) for initiation at CD4<500 cells/mm3, 
and 4.2% (4.0, 4.5) for initiation at CD4<350 cells/mm3. Compared with immediate 
initiation, the risk ratio (95% CI) was 1.02 (1.01, 1.03) under initiation at CD4<500 
cell/mm3, and 1.06 (1.03, 1.10) under initiation at CD4<350 cell/mm3 (Table 2). Compared 
with immediate initiation, the mean survival time at 7 years under initiation at CD4<500 
cells/mm3 and at CD4<350 cells/mm3 was 2 (1,2) and 5 (4,6) days shorter. The estimates 
did not materially change in sensitivity analyses (Appendix Table 2).
The estimated 7-year risk of the combined endpoint of AIDS-defining illness or death was 
7.1% (6.8, 7.3) for immediate initiation, 7.5% (7.2, 7.8) for initiation at CD4<500 cell/mm3, 
and 8.5% (8.2, 8.8) for initiation at CD4<350 cell/mm3. Compared with immediate 
initiation, the risk ratio (95% CI) was 1.06 (1.06, 1.07) under initiation at CD4<500 
cell/mm3, and 1.20 (1.17, 1.23) under initiation at CD4<350 cell/mm3. Figure 1 shows the 
estimated survival curves.
All estimated 7-year risks were lower in analyses restricted to the 17,612 individuals with 
baseline CD4 cell count>500 cells/mm3 and the 30,558 individuals with baseline CD4 cell 
count >350 cells/mm3 (Table 3).
The estimated 7-year risk of severe/moderate AIDS or death was 4.7% (4.3, 5.0) under 
immediate initiation, 4.8% (4.5, 5.1) under initiation at CD4<500 cells/mm3, and 5.2% (4.9, 
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5.4) under initiation at CD4<350 cells/mm3. Compared with immediate initiation, the risk 
ratio was 1.03 (1.02, 1.04) under initiation at CD4<500 cell/mm3 and 1.11 (1.07, 1.15) under 
initiation at CD4<350 cell/mm3. The estimated 7-year risk of tuberculosis was 1.20 (1.09, 
1.36) under immediate initiation, and 1.24 (1.15,1.41) and 1.34 (1.26,1.51) under initiation 
at CD4 initiation <500 and <350 cells/mm3.
Figure 2 shows the proportion of individuals considered in need of treatment by cART 
initiation strategy. At 1 year, 100%, 78%, and 58% of individuals were estimated to be on 
cART under immediate initiation, initiation at CD4<500 cell/mm3, and initiation under 
CD4<350 cell/mm3, respectively. The corresponding proportions at year 7 are 100%, 99%, 
and 92% (Appendix Table 3).
Figure 3 shows the proportion of individuals with virologically suppressed replication by 
cART initiation strategy. At 1 year, 58%, 46%, and 36% of individuals were estimated to be 
virologically suppressed under immediate initiation, initiation at CD4<500 cell/mm3, and 
initiation under CD4<350 cell/mm3, respectively. The corresponding proportions at year 7 
are 87%, 87%, and 84% (Appendix Table 4). The estimates were larger when suppressed 
virological suppression was defined as HIV-RNA<400 copies/mL (Appendix Figure 2).
Discussion
Our estimates from high-income countries in Europe and the USA indicate that, in a 
population with a fairly low CD4 count at HIV diagnosis, immediate initiation of cART 
increases survival and AIDS-free survival compared with initiation strategies based on CD4 
count. However, over a 7 year period, the average benefit was small both for survival (5 
days) and AIDS-free survival (21 days) when comparing immediate initiation with initiation 
at a CD4 count of less than 350 cells/mm3. For individuals with a CD4 count greater than 
500 cells/mm3 at HIV diagnosis, starting cART when the CD4 count fell below 350 
cells/mm3 increased the relative risk of death or diagnosis of AIDS by more than 50% when 
compared with immediate initiation.
Our estimates also indicate that the proportion of individuals with suppressed virological 
replication was greater for immediate universal cART initiation earlier in the follow-up. By 
7 years, all strategies resulted in estimated proportions of virological suppression between 
83 and 87%. At that time between 93% and 99% of individuals were estimated to be 
receiving cART under both CD4-based strategies.
Our findings from high-income countries complement the results from the Temprano12 and 
the HPTN 05210 trials. The Temprano trial randomised individuals with nadir CD4 cells 
count > 800 cells/mm3 to either immediate initiation or initiation when CD4 count drops 
below the threshold recommended by WHO (between 200 and 500 cells/mm3 depending of 
the year of recruitment). Immediate initiation reduced the risk of serious illness, including 
tuberculosis and death, by 44%. The HPTN 052 trial randomly assigned individuals in low 
and mid-income countries with CD4 count between 350 and 550 cells/mm3 to either 
immediate cART initiation or initiation at the earliest of CD4 dropping below 250 cells/mm3 
or a diagnosis of an AIDS-defining illness. A secondary analysis found that immediate 
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initiation reduced the risk of several clinical outcomes. Though these trials cover a shorter 
period than our study (2.5 versus 7 years) and use outdated CD4 cell count thresholds, a 
comparison with our estimates suggests that immediate initiation may be more beneficial in 
low-income countries, where tuberculosis and bacterial infections are more frequent, than in 
the high-income countries represented in our study.
Our results will also complement the START trial results, when they become available, for 
the subset of trial participants in high-income countries.34 In preliminary analyses, the data 
and safety monitoring board of the START trial reported that initiation of treatment at a 
CD4 count less than 350 cells/mm3 substantially increased the incidence of death or serious 
disease when compared with immediate initiation in individuals with CD4 counts higher 
than 500 cells per μL at baseline. We also estimated an increased risk with deferral of cART 
(52% after 7 years), but of smaller magnitude, perhaps reflecting residual confounding, 
different populations and periods, or both. Our analysis also provides estimates for all-cause 
mortality over 7 year follow-up in high income countries. When full results of the START 
trial are released, we will be able to do a more formal comparison between a randomized 
and an observational study assessing the benefits of early initiation of cART, which will be 
useful in informing adjustments that may be required in future analyses of longer term 
outcomes
Besides the length of follow-up, the main strengths of our study are the large sample size of 
over 55,0000 individuals and the setting in HIV clinics in Europe and United States that are 
representative of routine clinical practice. Therefore, our results should be generalisable to a 
population of HIV-infected, AIDS-free patients in high-income countries. Other 
observational studies of ART-naïve patients have compared clinical outcomes for cART 
initiation at different CD4 count thresholds,5-8 and have generally found that earlier 
initiation was beneficial. Of note, some of these observational studies included HIV cohorts 
that contributed data to our study, although we are using a more recent data update.
Our study has some limitations. First, we did not have information on non-fatal adverse 
effects. Because of longer exposure to antiretroviral treatment, patients who initiate cART 
early might be more susceptive to drug toxicity. Although the safety profiles of antiretroviral 
drugs has largely improved in the last decade, central nervous system,25,26 renal,27-29 bone30 
and cardiovascular31 toxicities have been reported in relation to drugs currently used in 
high-income countries. Second, like all observational studies the validity of our estimates 
relies on the assumption of no unmeasured confounding. Although we adjusted our models 
for time-varying CD4 count, HIV-RNA levels and AIDS diagnosis, the most important 
factors used by clinicians to decide when to start cART, we cannot exclude the possibility 
that unmeasured prognostic factors (e.g., hepatitis co-infection) could have influenced the 
decision to start cART.
The debate on the optimal strategy to initiate cART needs to take into consideration both the 
public health benefits, i.e., reduction of HIV transmission, and the benefits for HIV-infected 
individuals, i.e., increase in healthy life years. Our findings help quantify both types of 
benefits. A public health benefit of earlier initiation is implied by the greater proportion of 
virologically suppressed individuals, whchi will result in lower transmission to others. 
Page 8













However, the success of cART to prevent transmission depends also on HIV testing 
strategies. Since at least 30% to 80%32,33 of transmissions occur from individuals unaware 
of their HIV infection, early cART initiation, if implemented, should be put in place together 
with strategies to encourage HIV testing in early HIV disease.
Our findings also help quantify the individual benefits of earlier initiation in terms of 
slightly longer survival under the testing strategies present in the study populations. More 
work is needed to explore whether these small benefits are partly offset by higher risk of 
toxicity or development of drug resistance in the long term.
In analyses restricted to individuals with CD4 count>350 cells/mm3 at HIV diagnosis, the 
estimated 7-year risks of mortality and combined outcome mortality or AIDS-defining 
illness were <3% and <7%, respectively, for all cART initiation strategies. The higher risks 
(<4.2% and <9%, respectively) in the main analyses, which included approximately 50% 
individuals with CD4 count<350 cells/mm3 at HIV diagnosis, again suggest the importance 
of timely cART initiation and better HIV testing strategies.
Finally, our study enables us to quantify the degree to which earlier cART initiation results 
in increased proportions of individuals considered in need of treatment. The differences 
between cART initiation strategies decrease over time and become small at 7 years after 
HIV diagnosis. The early differences might be negligible when considering the total 
duration of cART, which is expected to be between 40 and 50 years35. More research is 
needed on the long-term cost-effectiveness of different cART initiation strategies after 
accounting for the impact on new transmissions.36,37
In conclusion, our estimates indicate that, compared with CD4-based strategies, immediate 
universal treatment slightly prolongs survival and AIDS-free survival and increases the 
proportions of individuals with suppressed virological replication and in need of treatment. 
However, a policy on whether cART is made available at HIV diagnosis irrespective of CD4 
count needs to consider many pieces of information—eg, longterm all-cause mortality, 
AIDS and non-AIDS morbidity, HIV transmission, the health-care setting, and costs that no 
one study can provide. Results from recently presented randomised trials indicate that there 
is a health benefit from immediate initiation of cART. Observational studies will continue to 
have a role in understanding the long-term effects of initiation of cART at high CD4 counts 
in routine clinical settings. Our results suggest that a focus on better and innovative HIV 
testing strategies might be as important, if not more, than discussions about early initiation 
of treatment.
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